Kanpiduo (Indapamide, Candesartan Cilexetil)

Candesartan cilexetil blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. Indapamide reduces sodium and chloride reabsorption in the distal renal tubule, increasing urine output and decreasing peripheral vascular resistance. Together they produce a synergistic antihypertensive effect.

The appropriate dose of Kanpiduo is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made according to individual therapeutic goals and tolerability.

Safety data for Kanpiduo in pregnancy are limited, and the product should be avoided unless the potential benefit justifies the risk. Candesartan is generally contraindicated in the second and third trimesters. Breastfeeding considerations should be discussed with a healthcare professional.

To place an order, submit an enquiry on the Kanpiduo product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Kanpiduo combines an ARB with a thiazide‑like diuretic, offering both vasodilation and diuretic effects in a single tablet. Compared with monotherapy, it can achieve better blood‑pressure control and may reduce pill burden, but clinicians must monitor for additive electrolyte changes and renal effects.

Kanpiduo tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Kanpiduo is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, hyperkalemia, acute kidney injury, angioedema, and rare blood‑cell abnormalities. Patients should be educated to seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or signs of kidney dysfunction.

Kanpiduo is contraindicated in patients with known hypersensitivity to either component, severe renal impairment, hyperkalemia, or those taking other potent ARBs or ACE inhibitors without careful monitoring. It should also be avoided in pregnancy, especially during the second and third trimesters.